XOMA Royalty Corporation acquires Pulmokine Inc. for $20 Million to add Seralutinib, a Phase 3 Asset, to its Portfolio
Acquiring Company
XOMA Royalty Corporation
Acquired Company
Pulmokine
BerkeleyRensselaerBiotechnologyHealth CareBiotechnologyHealth CareDescription
XOMA Royalty Corporation, a biotechnology royalty aggregator, has completed the acquisition of Pulmokine Inc. for $20 million. This acquisition adds Seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension (PAH), to XOMA Royalty's portfolio, reinforcing its commitment to helping biotech companies achieve their goal of improving human health.
Quick answer
XOMA Royalty Corporation is acquiring Pulmokine for $20 million, announced December 2, 2024. XOMA Royalty Corporation is based in Berkeley, California, United States.
- How much did XOMA Royalty Corporation pay for Pulmokine?
- The reported deal value is $20 million.
- What does XOMA Royalty Corporation do?
- XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.
- Where are XOMA Royalty Corporation and Pulmokine based?
- XOMA Royalty Corporation is based in Berkeley, California, United States. Pulmokine is based in Rensselaer, New York, United States.
- Who are the decision-makers at XOMA Royalty Corporation?
- Fundz holds 3 contacts at XOMA Royalty Corporation. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology and Health Care
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cycle Pharmaceuticals completes acquisition of Banner Life Sciences, LLC to expand MS product portfolio (January 13, 2025)
- Vivo Infusion completes acquisition of Neurology Institute of San Antonio and Vista Infusions to expand infusion services (January 9, 2025)
- ActiGraph completes acquisition of Biofourmis Connect to enhance digital health solutions (January 7, 2025)
- FINSIGHT completes acquisition of Credit Flow Research (CFR) to enhance its presence in the US fixed income market (January 6, 2025)
- Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease (January 5, 2025)
- OraSure Technologies completes acquisition of Sherlock Biosciences, Inc. to expand its innovation pipeline in molecular testing market (December 19, 2024)
Who to call at XOMA Royalty Corporation, and when
When XOMA Royalty Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day XOMA Royalty Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at XOMA Royalty Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at XOMA Royalty Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment XOMA Royalty Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Pulmokine?
Pulmokine was acquired by XOMA Royalty Corporation, based in Berkeley. The deal was reported on December 2, 2024. XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty Corporation is privately held and operates in Biotechnology.
When did XOMA Royalty Corporation acquire Pulmokine?
XOMA Royalty Corporation's acquisition of Pulmokine was reported on December 2, 2024. XOMA Royalty Corporation, a biotechnology royalty aggregator, has completed the acquisition of Pulmokine Inc. for $20 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Pulmokine do?
Pulmokine Inc. is a privately held company that has developed seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension (PAH). It is privately held, operating in Biotechnology, and is based in Rensselaer.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.